KRYS
Krystal Biotech·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 3
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
RSI Overbought
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About KRYS
Krystal Biotech, Inc.
A biotechnology company that develops pharmaceutical products for dermatological diseases
2100 Wharton Street, Suite 701, Pittsburgh, Pennsylvania 15203
--
Krystal Biotech, Inc., began operations in April 2016. In March 2017, they converted from a California limited liability company to a Delaware C-corporation and changed its name from Krystal Biotech, LLC to Krystal Biotech, Inc. The company is a biotechnology company focused on the development and commercialization of genetic medicines for patients with rare diseases. Using their patented platform based on engineered HSV-1, they created vectors that can effectively deliver therapeutic transgenes to cells of interest in multi-organ systems. The cell's own machinery then transcribes and translates encoded effectors to treat or prevent disease. They are vectors for non-invasive or minimally invasive routes of administration in the office of a healthcare professional or possibly in the patient's home by a healthcare professional. Their goal is to develop easy-to-use drugs that can significantly improve the lives of patients with rare and chronic diseases.
Earnings Call
Q1/2025
Estimate EPS1.52
Actual EPS1.2
Estimate Revenue96.21M
Actual Revenue88.18M
Krystal Biotech's Q1 2025: Navigating Contradictions in Reimbursement, Compliance, and Manufacturing Strategies
May 06,2025 02:45
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS1.44
Actual EPS1.29
Estimate Revenue91.96M
Actual Revenue96.04M
Contradictions Unveiled: Krystal Biotech's Q2 2025 Earnings Call Reveals Conflicting Insights on VYJUVEK Sales and Market Strategy
Aug 04,2025 12:51
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS1.12
Actual EPS2.66
Estimate Revenue93.42M
Actual Revenue97.80M
Krystal Biotech's Q3 2025 Earnings Call: Contradictions in U.S. vs. Ex-U.S. Revenue, Europe Launch Timelines, Manufacturing Process, and Patient Access
Nov 03,2025 12:04
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
KRYS has released its 2025 Q3 earnings. EPS was reported at 2.66, versus the expected 1.12, beating expectations. The chart below visualizes how KRYS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
KRYS has released its 2025 Q3 earnings report, with revenue of 97.80M, reflecting a YoY change of 16.65%, and net profit of 79.36M, showing a YoY change of 192.00%. The Sankey diagram below clearly presents KRYS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
